ClinicalTrials.gg
Active, not recruitingNCT06620237Updated Oct 21, 2026

BIO|MASTER.CSP Study

An interventional study of Implantation of the Solia CSP S pacing lead for LBBAP in Cardiac Pacing, Artificial, Cardiac Pacemaker, Artificial and Cardiac Resynchronization Therapy Devices, sponsored by Biotronik SE & Co. KG. Active, not recruiting at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Biotronik SE & Co. KG · Not applicable, Interventional, and Treatment

How we know

Updated Oct 21, 2026Study completion movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
152
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Bradycardia by Biotronik SE & Co. KG — 3 open to participants now, 4 under way, none of them phase 3. Bradycardia · Biotronik SE & Co. KG.

Planned enrollment
7th of 10
152 · median 193
Started
2024
with 1 other
No phase
8 of 15
1 open now
Registered
11th of 15
by date

Among the 15 studies in Bradycardia by Biotronik SE & Co. KG, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 with no phase, and was the 11th registered.

Bradycardia

317 studies on the registry are indexed under Bradycardia; 71 are open to participants now.

Browse Bradycardia studies →

Open to participants now

3 of the 15 studies in Bradycardia by Biotronik SE & Co. KG are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 51 Bradycardia studies recruiting now, 34 (67%) set no upper age limit and 9 (18%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Bradycardia by Biotronik SE & Co. KG, or all of them as a file.
02

Study summary

The goal of this clinical study is to test the clinical safety and performance of the Amvia pacemakers and the Solia CSP S lead when used for left bundle branch area pacing (LBBAP). The patient population consist of patients with cardiac pacemaker indication or cardiac resynchronization therapy indication and intended for implantation of a system with left bundle branch area stimulation. Participants will visit sites at enrollment in the study, at implantation and pre-hospital discharge, 1-, 6- and 12-month follow-up visits. Additional annual follow-up(s) may apply until study termination after regulatory approval of Solia CSP S. The total duration of the clinical investigation is expected to be until September 2027, with last patient out (LPO). During the visits the regular pacemaker and lead measurement are performed. A 12-lead ECG is recorded to document intrinsic and ventricularly paced heart rhythm to assess left bundle branch area pacing. Programming of the pacemakers will be done according to the participant´s therapeutical needs.

The study will be conducted in approximately 18 sites in Europe, Australia and New Zealand where more than one physician per site are expected to participate.

03

Conditions studied

  • Cardiac Pacing, Artificial
  • Cardiac Pacemaker, Artificial
  • Cardiac Resynchronization Therapy Devices
  • Bradycardia
  • Conduction Disorder
  • Conduction Defect, Cardiac
  • Heart Failure

Keywords

  • Conduction system pacing (CSP)
  • Left bundle branch area pacing (LBBAP)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For patient enrollment in the study all of the following inclusion criteria have to be fulfilled at the time of enrollment:

  • Standard indication for de novo pacemaker implantation or cardiac resynchronization therapy (CRT)
  • Patient is intended for implantation of a pacemaker or CRT-P system with left bundle branch area stimulation
  • Ability to understand the nature of the study
  • Ability and willingness to perform all follow-up visits at the study site
  • Ability and willingness to use the CardioMessenger and acceptance of the BIOTRONIK Home Monitoring concept

Exclusion criteria

Exclusion Criteria:

Enrollment of a patient is not permitted if at least one of the following criteria is fulfilled:

  • Planned cardiac surgical procedures or interventional measures other than the study procedure within the next 12 months
  • Expected to receive heart transplantation or ventricular assist device within 12 months
  • Life-expectancy less than 12 months
  • Pregnant or breast feeding
  • Age less than 18 years
  • Participation in another interventional clinical investigation (according to the definition given in the CIP)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • No intervention
    LBBAP Amvia

    All patients with successful implantation of Amvia pacemaker and a lead in a position intended for LBBA pacing.

  • Experimental
    LBBAP Solia CSP S

    All patients with successful implantation of a Solia CSP S lead in LBB area. Additionally, all patients with a non-successful Solia CSP S implantation attempt in which an ADE (adverse device effect) or SADE (serious adverse device effect) related to the Solia CSP S lead occurred.

    Device: Implantation of the Solia CSP S pacing lead for LBBAP

Interventions

  • DeviceImplantation of the Solia CSP S pacing lead for LBBAP

    Left bundle branch area pacing using a Solia CSP S lead

06

What researchers measure

Primary outcomes

  1. Amvia related SADE-d free rate

    rate of serious adverse device effects possible, probable or causal related to the Amvia pacemaker

    Time frame: 6 months (183 days) after implantation

  2. Solia CSP S related SADE-d free rate

    rate of serious adverse device effects possible, probable or causal related to the Solia CSP S lead

    Time frame: 6 months (183 days) after implantation

Secondary outcomes

  1. Amvia related SADE-d free rate

    Rate of serious adverse device effects possible, probable or causal related to the Amvia pacemaker

    Time frame: 12 months (365 days) after implantation

  2. Solia CSP S related SADE-d free rate

    Rate of serious adverse device effects possible, probable or causal related to the Solia CSP S lead

    Time frame: 12 months (365 days) after implantation

  3. Rate of successful acute CSP implantation of Solia CSP S

    All implantations, in which the investigator decides to leave the Solia CSP S pacing lead permanently in the conduction system, are counted as acute success.

    Time frame: At the day of implantation

  4. Sensing performance

    Investigators will be asked whether the sensing is adequate (yes/no decision)

    Time frame: At the day of implantation and at the date of each in-office patient follow-up visit (1-, 6-, 12-month follow-up, and annual follow-up*) * please refer to study duration in study description section

  5. Pacing performance

    Investigators will be asked whether the pacing is adequate (yes/no decision)

    Time frame: At the day of implantation and at the date of each in-office patient follow-up visit (1-, 6-, 12-month follow-up, and annual follow-up*) * please refer to study duration in study description section

  6. Physiologic ventricular excitation

    Investigators are asked to assess whether pacing in the left bundle branch area is still present based on the 12-lead ECG recording

    Time frame: At the day of implantation and at the date of each in-office patient follow-up visit (1-, 6-, 12-month follow-up, and annual follow-up*) * please refer to study duration in study description section

  7. Mid-term change in LVEF

    Collection of left ventricular ejection fraction (LVEF) values

    Time frame: At baseline, at the 6-month follow-up, at the 12-month follow-up and at all following annual in-office follow-ups*, if applicable; * please refer to study duration in study description section

  8. Mid-term change in LVESV

    Collection of left ventricular ejection systolic volume (LVESV) values

    Time frame: At baseline, at the 6-month follow-up, at the 12-month follow-up and at all following annual in-office follow-ups*, if applicable; * please refer to study duration in study description section

  9. Mid-term change in quality of life, EQ-5D-5L (EuroQol) questionnaire

    Collection of health-related quality of life questionnaires from the patient to monitor mid-term changes in the quality of life, analysis and reporting according to EuroQol methodology

    Time frame: At baseline after patient enrollment prior to implantation, at the date of 6-month follow-up, at the 12-month follow-up and at all following annual in-office follow-ups*, if applicable; * please refer to study duration in study description section

  10. Mid-term change in quality of life, SF-36 (Short Form Health Survey) questionnaire

    Collection of health-related quality of life questionnaires from the patient to monitor mid-term changes in the quality of life, analysis and reporting according to item short form health survey (SF-36) standard methodology

    Time frame: At baseline after patient enrollment prior to implantation, at the date of 6-month follow-up, at the 12-month follow-up and at all following annual in-office follow-ups*, if applicable; * please refer to study duration in study description section

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized data may be shared with qualified healthcare practitioners or academic researchers upon request and with permission of BIOTRONIK. Requests shall be sent to the Clinical Research Department of BIOTRONIK.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 24 months after the start.

Of 36 industry-sponsored interventional studies with no phase under Bradycardia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 24 months is above that.

Counting every sponsor, half of 83 studies reached it within 21 months; a quarter within 12 and three quarters within 38.

Primary completion moved once since we started tracking on Sep 25, 2026: Apr 2026 → Oct 2026, on Oct 1, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Dec 2026, on Oct 21, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Oct 1, 2024
StartActual
Oct 4, 2024
Primary completionEst.
Oct 2026was Apr 2026
CompletionEst.
Dec 2026was Sep 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 2026→Oct 2026
Oct 1, 2026
Study completion
Sep 2027→Dec 2026
Oct 21, 2026
Show all 2 updates
  1. Oct 21, 2026
    Study completion Sep 2027→Dec 2026
    + 1 other change: verification date
  2. Oct 1, 2026
    Primary completion Apr 2026→Oct 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06620237
Responsible party
Sponsor
First posted
Oct 1, 2024
Start date
Oct 4, 2024
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 21, 2026

Study contacts

Jan De Pooter, MD, PhD
study chair · University Hospital Ghent, Gent (Belgium)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion